NM
BXRX

Newtyn Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Newtyn Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-199
Closed -$1.93M – 65
2019
Q4 		$1.93M Buy
+199
New +$1.7M 0.18% 41

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Newtyn Management's BXRX Position: Q1 2020 in Review

Newtyn Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2020, closing a stake of 199 shares — an estimated $1.93M sold.

Newtyn Management first reported a position in BXRX in Q4 2019 and held it in 1 quarter. The position peaked at $1.93M in Q4 2019. 47 funds tracked by Wall St. Rank hold BXRX as of Q1 2020.

  • Newtyn Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Newtyn Management sold 199 Baudax Bio, Inc. Common Stock shares in Q1 2020, an estimated $1.93M.
  • Newtyn Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Newtyn Management's Baudax Bio, Inc. Common Stock position peaked at $1.93M in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2020.

Based on Newtyn Management's 13F filing for Q1 2020, filed 15 May 2020.